secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001804220-23-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q1 revenue up 7% to $3.16B; GAAP EPS $7.17; non-GAAP $10.09
---------------------------------------------------------------------

- Q1 total revenue $3.162B (+7% YoY); GAAP net income $818M (-16%); non-GAAP net income $1.168B (-11%).
- EYLEA U.S. net sales $1.43B (-6% YoY); Dupixent global net sales $2.49B (+37%, recorded by Sanofi).
- Aflibercept 8 mg BLA accepted for FDA priority review; target action date June 27, 2023 for wet AMD and DME.
- Dupixent Phase 3 COPD trial met endpoints: 30% reduction in exacerbations; first biologic to show benefit in COPD.
- Full-year 2023 guidance: GAAP R&D raised to $4.225-4.465B; GAAP SG&A raised to $2.49-2.68B; gross margin lowered to 87-89%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/0001804220-23-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422023000015/regn-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001804220-23-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer